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Abstract 
Viral oncogenes are responsible for oncogenesis resulting from persistent virus infection. 
Although different human tumor viruses express different viral oncogenes and induce dif-
ferent tumors, their oncoproteins often target similar sets of cellular tumor suppressors or 
signal pathways to immortalize and/or transform infected cells. Expression of the viral E6 and 
E7 oncogenes in papillomavirus, E1A and E1B oncogenes in adenovirus, large T and small t 
antigen in polyomavirus, and Tax oncogene in HTLV-1 are regulated by alternative RNA 
splicing. However, this regulation is only partially understood. DNA tumor viruses also en-
code noncoding RNAs, including viral microRNAs, that disturb normal cell functions. Among 
the determined viral microRNA precursors, EBV encodes 25 from two major clusters (BART 
and BHRF1), KSHV encodes 12 from a latent region, human polyomavirus MCV produce only 
one microRNA from the late region antisense to early transcripts, but HPVs appears to 
produce no viral microRNAs. 
Key words: Human papillomaviruses, Epstein-Barr virus, Kaposi sarcoma-associated herpesvirus, 
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A BRIEF HISTORY 
  In  1909,  a  farmer  brought  Dr.  Francis  Peyton 
Rous,  a  junior  faculty  member  then  at  Rockefeller 
University, a hen that had a breast tumor. Rous per-
formed an autopsy, extracted tumor cells, and injected 
the cells into other hens, which then developed sar-
coma [1]. This was the first experimental proof of an 
infectious etiologic agent of cancer, and the chicken 
sarcoma-inducing  RNA  virus  was  subsequently 
named the Rous sarcoma virus. After a half-century 
debate on whether viruses truly cause cancer, Rous 
was eventually awarded the Nobel Prize in Medicine 
and  Physiology  in  1966  for  his  discovery  of  tu-
mor-inducing  viruses.  It  is  now  estimated  that 
20%-25% of human cancers worldwide have a known 
viral etiology [2]. 
 Early pioneering efforts on tumor-inducing vi-
ruses were mainly focused on avian and small-animal 
retroviruses, a group of RNA viruses containing an 
RNA-dependent  DNA  polymerase  (reverse  tran-
scriptase), and it was thought that there were no sim-
ilar viruses in humans. Demonstration in 1980 of the 
first human retrovirus, human T-cell leukemia virus 
type 1 (HTLV-1), which causes adult T-cell leukemia, 
was  therefore  a  landmark  achievement  [3-5].  Later, 
HTLV-2, which is far less pathogenic than HTLV-1, 
was isolated from a hairy T-cell leukemia [6], but soon 
was demonstrated not to be the agent of the malig-
nant  hematological  disease.  HTLV-3  [7]  and  -4  [8] 
have been discovered recently as new members of the Int. J. Biol. Sci. 2010, 6 
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HTLV family in central Africa, but their association 
with human diseases remains unclear [9].  
 Another line of investigation was to determine 
whether human DNA viruses play an etiological role 
in human cancers similar to the role of animal DNA 
viruses, several of which can easily transform rodent 
cells in culture and induce tumors when injected into 
animals.  This  effort  initially  led  to  associate  herpes 
simplex virus type 2 (HSV2) with the development of 
cervical cancer [10,11], but subsequently human pa-
pillomaviruses (HPVs) were proven to be the causa-
tive agent in the development of cervical cancer [12]. 
Dr. Harald zur Hausen of Germany won the Nobel 
Prize  in  2008  for  his  discovery  in  1983  that  HPVs 
cause cervical cancer.  
HUMAN DNA AND RNA TUMOR 
VIRUSES 
 Tumor viruses can be classified into two groups 
based  on  their  genetic  material,  as  summarized  in 
Table  1.  Cancer-causing  DNA  tumor  viruses  and 
RNA-containing  retroviruses  have  been  extensively 
investigated, and this review will be focused more on 
human DNA and RNA tumor viruses, instead of oth-
er animal tumor viruses. 
 
Table 1. Human oncogenic viruses. 
 
 
 
1. Human DNA tumor viruses 
HPVs 
 High-risk  or  oncogenic  HPVs  are  etiological 
agents of cervical cancer. Among the high-risk HPVs, 
HPV16 and HPV18 are the principal causes of cervical 
cancer as well as several other tumor types  [13]. A 
characteristic of infection by these HPVs is that the 
viral genomes are commonly integrated into the can-
cer  cell  genome.  Two  principal  viral  oncoproteins 
involved  in  cervical  carcinogenesis  are  E6  and  E7, 
which  destabilize,  respectively,  two  cellular  tumor 
suppressors, p53 and pRb [14]. HPVs are transmitted 
primarily  through  sexual  contact,  and,  as  human 
cancer viruses, have been the best studied of the tu-
mor viruses. The US Food and Drug Administration 
(FDA) in June 2006 approved Gardasil, the first cancer 
vaccine, for use in females 9-26 years of age to prevent 
cervical cancer, precancerous genital lesions, and ge-
nital  warts  caused  by  HPV6,  HPV11,  HPV16,  and 
HPV18 [15]. 
Epstein-Barr virus (EBV) 
 EBV primarily causes infectious mononucleosis, 
but also contributes to the pathogenesis of four hu-
man tumors: the African form of Burkitt lymphoma, 
B-cell  lymphomas  in  individuals  with  immunosup-
pression,  nasopharyngeal  carcinoma  (NPC)  in  sou-
theastern Asia, and some kinds of Hodgkin disease. 
EBV  infects  B  lymphocytes,  but  does  not  replicate 
within  the  B  cells;  instead,  it  transforms  them  into 
lymphoblasts,  which  have  an  indefinite  life  span, 
rendering these cells immortal. EBV encodes a viral 
oncogene,  LMP1  (latent  membrane  protein-1  or 
BNLF1). LMP1 is expressed in EBV-associated lym-
phoma and is essential for B-cell transformation and 
for disruption of cellular signal transduction [16-18]. 
Although the EBV nuclear antigen 1 (EBNA1) is one 
of the earliest viral proteins expressed after infection Int. J. Biol. Sci. 2010, 6 
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and is the only latent protein consistently expressed in 
viral-associated  tumors,  recent  results  indicate  that 
EBNA1  is  not  a  viral  oncoprotein  [19,20].  BARF1 
(BamHI-A reading frame-1) is also an early gene but is 
expressed as a latent gene in most NPCs [21]. Recent 
studies have suggested that BARF1 may have an im-
portant role in NPC oncogenesis [22,23].  
Kaposi sarcoma-associated herpesvirus (KSHV) 
 KSHV or human herpesvirus 8 (HHV8) infection 
is associated with all forms of Kaposi sarcoma, pri-
mary effusion lymphoma or body cavity–based B-cell 
lymphoma,  and  multicentric  Castleman  disease. 
KSHV  encodes  a  viral  G  protein–coupled  receptor 
(vGPCR) that presumably functions as a viral onco-
gene  in  immortalization  of  human  endothelial  cells 
and  induction  of  angioproliferative  tumors  [24,25]. 
KSHV vGPCR is not a split gene and thus has no RNA 
splicing in its expression. 
Human polyomaviruses 
 The  most  important  member  in  this  family  is 
simian virus 40 (SV40), one of the most common latent 
viruses of rhesus monkeys. For decades, SV40 which 
does  not  infect  human  has  attracted  the  interest  of 
many investigators in the field of cancer research be-
cause of its characteristic tumor antigens (T antigens) 
that  can  cause  malignant  cell  transformation.  Al-
though two human polyomaviruses, BK virus and JC 
virus,  have  been  described  as  oncogenic  in  rodents 
and nonhuman primates, whether these two viruses 
have any roles in human cancer is not clear. Recently, 
a new human polyomavirus, Merkel cell polyomavi-
rus  (MCV),  was  discovered  in  ~80%  of  Merkel  cell 
carcinomas (MCCs) [26]. An established MCC cell line 
contains monoclonal MCV DNA integration. The in-
tegrated MCV DNA encodes a mutant T antigen that 
prevents autoactivation of integrated virus replication 
[27]. Interestingly, MCV and two new human polyo-
maviruses,  polyomavirus-6  (HPyV6)  and  HPyV7, 
appear to inhabit healthy human skin with 40% de-
tection rate by a rolling cycle amplification technique 
[28] and approximately 88% of adult subjects without 
MCC were MCV seropositive [29].  
Human adenoviruses 
 Human adenoviruses are a group of small DNA 
viruses  that  commonly  cause  respiratory  infections. 
Human  adenoviruses  have  not  been  linked  to  any 
human cancer, but some serotypes, such as adenovi-
rus types 2, 5, 12,  18, and 31,  are capable of  trans-
forming rodent cells in culture and inducing tumors 
in  hamsters  or  rats.  Two  viral  oncogenes,  E1A  and 
E1B, have been identified as responsible for the ade-
novirus tumorigenicity and thus have served as use-
ful  tools  for  studying  many  important  cellular 
processes in tumor biology [30].  
Hepatitis B virus (HBV) 
 HBV  is  endemic  in  Southeast  Asia  and 
sub-Saharan  Africa.  Epidemiological  observations 
and  experimental  evidence  in  animal  models  have 
established a clear association between HBV infection 
and liver cancer. Although the precise role of HBV in 
causing  liver  cancer  is  not  yet  understood,  some 
compelling  evidence  suggests  that  the  HBx  gene 
could be a viral oncogene [31], as its protein product 
can disrupt signal transduction and deregulates cell 
growth [32]. Recent studies indicate that HBx func-
tions through the inhibition of proteasome activities 
to  enhance  HBV  replication  in  vivo  [33].  HBx  also 
binds  to  and  enhances  the  enzymatic  activity  of 
phosphatidylinositol  3-kinase  class  III,  an  enzyme 
critical for the initiation of autophagy [34]. HBx is not 
a split gene and thus there is no RNA splicing in its 
expression. 
2. Human RNA tumor viruses 
HTLV-1 
 HTLV-1–associated  adult  T-cell  leuke-
mia/lymphoma is endemic in the southern islands of 
Japan, the Caribbean basin, and South Africa. HTLV-1 
infects CD4+ T lymphocytes, and infected T cells can 
be transmitted via sexual intercourse, blood transfu-
sion, or breast feeding. Only about 1 percent of in-
fected  individuals  will  develop  leukemia,  and  then 
only after a period of 20 to 30 years of asymptomatic 
infection [35]. 
 All  members  of  the  HTLV  family  differ  from 
other oncogenic retroviruses in that they do not con-
tain viral homologues of cellular proto-oncogenes and 
do not integrate into specific sites of the human ge-
nome to disrupt proto-oncogenes. Although the me-
chanism of transformation is not clear, the viral on-
coprotein Tax, which promotes transcription and cell 
cycle progression, may be involved in setting up an 
autocrine  (self-stimulating)  loop  that  causes  conti-
nuous proliferation of infected T cells [36]. 
Xenotropic murine leukemia virus–related virus (XMRV) 
in human prostate cancer 
 Recently, Dong et al claimed that they discov-
ered  XMRV  as  a  new  human  retrovirus  associated 
with prostate cancer. XMRV was isolated from pros-
tate cancer tissue from patients homozygous for re-
duced  enzyme  activity  of  RNase  L  due  to  a  single 
amino acid substitution and is susceptible to inhibi-
tion by interferon [37]. XMRV infection might be also 
associated  with  chronic  fatigue  syndrome  [38-40]. Int. J. Biol. Sci. 2010, 6 
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XPR1 (xenotropic and polytropic retrovirus receptor 
1) is the receptor for XMRV infection [41]. However, 
recent reports from other groups appear controversial 
for a possible role of XMRV in prostate cancer and in 
chronic fatigue syndrome [42-47].  
Hepatitis C virus (HCV) 
 HCV  belongs  to  the  flavivirus  family.  Its 
plus-strand RNA genome carries a long open reading 
frame (ORF) encoding a polyprotein precursor of 3010 
amino acids, which can be cleaved into ten different 
proteins  (three  structural  and  seven  nonstructural). 
Although HCV oncogenesis is not well understood, 
persistent HCV infection is a prerequisite for the de-
velopment of HCV-associated liver cancer [48]. There 
are  no  oncogenes  in  the  viral  genome,  but  liv-
er-specific  miR-122  is  required  for  HCV  replication 
[49].  
VIRAL ONCOGENES AND THEIR 
FUNCTIONS 
E6 and E7 oncogenes in high-risk HPVs 
 HPV E6 and E7 from high-risk HPV types have 
the capacity to immortalize and transform keratino-
cytes and epithelial cells. Low-risk or non-oncogenic 
HPV E6 and E7, however, lack such biological activity 
[50-56]. Biochemically, high-risk E6 but not low-risk 
E6  interacts  with  E6AP  and  the  tumor  suppressor 
protein  p53  to  induce  ubiquitination-mediated  de-
gradation of p53[57-59]. An E6 F47R mutant is defec-
tive  for  polyubiquitination  and  degradation  of  p53 
[60,61].  High-risk  E7  and  not  low-risk  E7  interacts 
with  the  pRb  tumor  suppressor  protein  via  the 
LXCXE motif in the E7 CR2 domain to promote cell 
cycle progression [58,59,62-64]. Thus, interaction with 
cellular tumor suppressor proteins and perturbation 
of normal cell cycle control by high-risk E6 and E7 are 
believed to be the most important influence for ma-
lignant  conversion  [65-67].  In  this  regard,  E6  from 
HPV16  (16E6),  a  high-risk  type,  binds  E6AP  more 
strongly and drives the degradation of p53 more effi-
ciently than 18E6 [59]. In contrast, low-risk 11E6 has 
minimal binding affinity for E6AP [68] and influences 
the degradation of p53 only weakly in vivo [69]. Un-
der hypoxic conditions, high-risk E6 also inactivates 
the  CYLD  tumor  suppressor  through  interactions 
with CYLD deubiquitinase to allow unrestricted ac-
tivation of NF-κB [70]. 
 The full-length oncoprotein E6 is a basic nuclear 
protein (~18 kDa) composed of ~150 amino acid (aa) 
residues. Similar to E6 proteins encoded by other pa-
pillomaviruses, the 16E6 which has been extensively 
analyzed,  contains  four  zinc-binding  motifs 
(Cys-X-X-Cys)  and  forms  two  Cys/Cys  fingers  that 
bind zinc directly [71]. 16E6 also contains a PDZ do-
main–binding motif at its C-terminal extremity [72,73] 
and three nuclear localization signals (NLSs) [74] (Fig. 
1A). Besides the ability to immortalize and transform 
cells and induce p53 degradation, 16E6 is known to be 
functionally involved in regulating gene transcription 
[75,76]. In addition to its effect on p53, 16E6 can inte-
ract with other transcription factors and coactivators, 
including  p300/CBP  [77,78],  IRF-3  [79],  and  c-Myc 
[80]. The 16E6–cMyc interaction induces transcription 
of h-TERT to promote cell immortalization [81,82]. In 
addition, 16E6 is an RNA binding protein and inte-
racts  with  cellular  splicing  factors  and  RNA  via its 
C-terminal  NLS3  to  regulate  splicing  of  E6E7  bici-
stronic  RNAs  [83].  The  multifunctional  activity  of 
16E6 is not restricted to the nucleus, because it can act 
as  a  regulator  of  signal  transduction  through  inte-
racting  with  cytoplasmic  E6BP  (Erc55)  [84],  E6TP 
[85-87],  paxillin  [88],  TNFR1  [89],  protein  tyrosine 
phosphatase  H1  [90],  and  PDZ  proteins  such  as 
SAP97/hDlg  [91,92]  and  MAGI-1  [73].  Other  E6 
partner proteins have been summarized recently in a 
detailed  review  [14].  Taken  together,  these  interac-
tions  suggest  that  16E6  and  presumably  other 
high-risk  E6s  can  be  regarded  as  multifaceted  viral 
proteins with characteristic and distinct activities in 
the nucleus and cytoplasm of the cells they infect. 
 The full-length oncoprotein E7 is a nuclear pro-
tein containing ~100 aa residues. The N-terminus of 
E7 contains sequence similarity to a portion of CR1 
and  the  entire  CR2  of  adenovirus  E1A  and  related 
sequences in SV40 T antigen. Oncogenic E7 binds pRB 
and the related pocket proteins p107 and p130 with 
high affinity via the LXCXE motif in CR2 (Fig. 1B), 
whereas low-risk or non-oncogenic E7 binds pRB with 
much lower efficiency. Oncogenic E7 induces the de-
gradation  of  pRB  by  interacting  with  the  cullin  2 
ubiquitin ligase complex [93]. The C-terminus of E7 
may be involved in zinc-binding [94]. E7 contains a 
nuclear localization signal in the N-terminal domain 
(aa 1-37) [95]. In addition to its cellular transformation 
activities, oncogenic E7 also plays a role in the viral 
life cycle [96] and affects many other cellular activities 
in HPV-infected cells. E7 dysregulates the cell cycle by 
stabilizing p21 [97,98] and upregulating p16 expres-
sion [99]. Oncogenic E7 induces mitotic defects and 
aneuploidy  by  inducing  centrosome  abnormalities 
through its association with the centrosomal regulator 
γ-tubulin;  this  inhibits  γ-tubulin  recruitment  to  the 
centrosome [100] and leads to chromosomal instabil-
ity. More recently, HPV16 E7 expression was shown 
to  complement  the  requirement  of  RKO  colorectal 
cancer  cells  for  CDK6,  ERBB3,  FYN,  AAK1,  and 
TSSK2 for cell survival [101]. As both high-risk and Int. J. Biol. Sci. 2010, 6 
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low-risk  HPV  E7s  interact  with  p300  [102],  PCAF 
[103], steroid receptor coactivator 1  [104],  and p600 
[105], these interactions do not appear to be sufficient 
to  mediate  the  transformation  function  of  HPV  E7. 
Other E7 partner proteins have been summarized in 
two recent reviews [14,106].  
 
 
Figure  1. Schematic structures of oncoproteins E6 and E7. A. Protein structure and functions of HPV16 E6. Four 
zinc-binding motifs are shown as grey boxes. The F47 position in E6 appears to be responsible for p53 destabilization [61]. 
Nuclear localization signals (NLS) [74] and the PDZ-binding domain in the protein are indicated by underlines. B. Protein 
structure and functions of HPV16 E7. Relative locations of the regions with sequence motifs similar to a portion of con-
served region 1 (CR1) and the entire CR2 of adenovirus E1A are shown with the pRB-binding site LXCXE in the CR2. Grey 
boxes indicate zinc-binding motifs. CKII, casein kinase II phosphorylation sites. Arrows in this figure and the following figures 
for individual proteins indicate functions of the protein, not its domains or motifs. 
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E1A and E1B in human adenoviruses  
 The adenovirus genome encodes two viral on-
cogenes, E1A and E1B, positioned side-by-side in the 
left 11.2% of the genome. After an adenovirus infects a 
human  cell,  the  first  viral  proteins  that  are  synthe-
sized are products of the E1A region. The full-length 
E1A protein (289R) is a nuclear protein consisting of 
289 aa residues and has four conserved regions: CR1 
at the N-terminus, CR2 and CR3 in the middle, and 
CR4 at the C-terminus (Fig. 2A).  
 
 
Figure 2. Schematic structures of adenovirus E1A protein and mRNAs. A. Structure of E1A protein (full-length 289R 
variant) and its biological functions. Four conserved regions (CR1-CR4) in E1A and mapped domains in E1A are diagramed 
[30]. B. RNA structure and alternative spliced species of E1A pre-mRNA. A bidirectional splicing enhancer (BSE) is shown in 
exon 2 in green, and cellular splicing factors or regulators that control selection of each splice site are indicated by arrows. 
The panel is modified from reference [269], with permission. Dotted lines indicate splicing directions. Int. J. Biol. Sci. 2010, 6 
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The expression of a functional full-length E1A is 
necessary for the transactivation of the other adeno-
virus early genes, including E1B. E1A also expresses a 
truncated form or small E1A with 243 aa residues that 
lacks a CR3 region due to alternative RNA splicing 
and thus lacks the transactivation activity. Both E1A 
proteins (289R and 243R) are most abundant during 
early viral infection and display similar functions in 
the induction of cellular DNA synthesis, inactivation 
of pRB (equivalent to the HPV E7 oncoprotein), sti-
mulation of cellular transformation, and promotion of 
apoptosis  through  protein-protein  interactions.  E1A 
CR2 binds pRB and the related pocket proteins p107 
and p130 with high affinity, and together with a low-
er-affinity binding region within CR1 displaces pRB 
proteins from E2F transcription factors, resulting in 
derepression of cell cycle genes. The N-terminus and 
residues  in  CR1  which  are  required  for  E1A  trans-
forming activity bind to p300/CBP, PCAF, GCN5, and 
p400 to regulate chromatin structure. Recent studies 
have shown that the E1A–p300/CBP interaction re-
duces  acetylation  of  cellular  histone  H3  lysine  18 
(H3K18), because CBP and p300 are required for ace-
tylation at H3K18 [107]. E1A binds transiently and in 
a  time-dependent  manner  to  promoters  of  a  large 
number of genes involved in cell cycle and growth, 
antiviral  activity,  and  development  and  differentia-
tion, but this temporal order of E1A binding requires 
its  interactions  with  p300/CBP  and  pRB  proteins 
[108].  
 The E1B gene encodes two major proteins, 19K 
(176R) and 55K (496R), which are both independently 
capable of promoting cell transformation and uncon-
trolled  cell  growth  in  cooperation  with  E1A.  Both 
proteins are translated from the same mRNA of ~2.28 
kb, but the ORF of E1B-55K is accessed by an internal 
initiation site and uses an alternative ORF [109]. Thus, 
E1B-55K has no sequence homology to the E1B-19K 
protein. The major roles of E1B-19K and E1B-55K in 
viral infection are suppression of host cell apoptosis 
and, in rodent cells, promotion of complete transfor-
mation in cooperation with E1A. Functional motifs of 
E1B-55K have been mapped as shown in Fig. 3A. Ex-
pression of E1A alone is not sufficient for efficiently 
transforming primary cells or inducing lung carcino-
genesis  in  transgenic  E1A  mice,  but  E1B-19K  and 
E1B-55K  can  individually  cooperate  with  E1A  to 
produce a fully transformed tumorigenic phenotype 
and to induce lung carcinogenesis in transgenic mice 
expressing both E1A and E1B transgenes [110]. This is 
at least in part a consequence of (1) E1B-19K inhibition 
of the co-oligomerization of the Bcl-2 family proteins 
BAK  and  BAX,  leading  to  blockade  of  cas-
pase-mediated  apoptosis,  and  (2)  the  interaction  of 
E1B-55K with p53 [111] for p53 degradation and thus 
the  inhibition  of  p53  functions  [30].  The  full-length 
(55K) E1B is required for mRNA export of viral late 
mRNA [112]. 
Large T and small t antigens in human polyoma-
viruses 
 Human  polyomaviruses  encode  two  onco-
proteins, large T (LT) antigen and small t (st) antigen, 
due to alternative RNA splicing. Both LT and st are 
viral nonstructural proteins expressed early in virus 
infection.  Like SV40  T antigens,  whose roles in cell 
transformation  have  been  investigated  extensively, 
human polyomaviral LT inactivates two cellular tu-
mor suppressor proteins, p53 and pRB, by direct pro-
tein-protein interactions, and st also inactivates cellu-
lar  protein  phosphatase  2A  (PP2A)  through  pro-
tein-protein  interactions.  Experimentally,  coexpres-
sion  of  st  enhances  the  transforming  ability  of  LT 
[113]. 
 Structurally, LT can be divided into several re-
gions [114]. The N-terminal J domain overlaps with 
two highly conserved regions (CR1 and CR2) and is 
the binding site for the Hsc70 family of chaperones, 
which  promote  the  proper  folding  of  proteins  after 
translation. Both LT and st have this domain with the 
same aa residues derived from the same exon 1 re-
gion, but the remaining parts of each protein are dif-
ferent. A pRB-binding region is close to the J domain 
in LT and contains an LXCXE motif essential for its 
interaction  with  the  pRB  family  members.  The 
C-terminal ATPase/DNA helicase region of LT over-
laps with a p53-binding region. Together with a DNA 
origin–binding domain in the central portion of LT, 
this region is responsible for viral genome replication 
(Fig. 4A). LT inactivates p53 via its p53-binding site, 
but the LT–p53 complex activates insulin-like growth 
factor I (IGF-I) transcription to promote malignant cell 
growth [115]. In contrast, st lacks all  of  the LT do-
mains  but  contains  a  unique  PP2A-binding  site.  Of 
note, binding of st inhibits the phosphatase activity of 
cellular  PP2A,  an  essential  regulator  of  numerous 
signaling pathways [116]. 
 Interestingly, LT mutation appears common in 
the human MCV genome isolated from MCCs. The 
MCC tumor-derived LT sequences harbor mutations 
prematurely  truncating  exon  2,  which  encodes  the 
MCV LT ATPase/helicase. Consequently, the result-
ing MCV LT is deficient in viral replication, whereas 
pRB targeting is spared in cancer cells [27]. However, 
recent studies indicate that MCV T antigen expression 
is  necessary  for  the  maintenance  of  MCV-positive 
MCC [117]. 
 Int. J. Biol. Sci. 2010, 6 
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Figure 3. Schematic structures of adenovirus E1B protein and mRNAs. A. E1B protein structure and its biological functions. 
NES, nuclear export sequences; NLS, nuclear localization sequences; RNP, ribonucleoprotein motif; CKI/II, casein kinase I/II 
phosphorylation site. See other reference for more information about E1B [270]. B. RNA structure and alternatively spliced 
species of E1B pre-mRNA.  Int. J. Biol. Sci. 2010, 6 
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Figure 4. Diagrammatic representation of the SV40 large T antigen and its RNA splicing. A. Schematic protein structure of 
SV40 large T antigen. J, DnaJ domain; OBD, origin DNA-binding domain. B. Alternative splicing of SV40 T antigen pre-mRNA 
leads to production of Large T, 17K T, and small t mRNAs. Black dots indicate stop codon locations on spliced RNAs.  
 
 
 
LMP1 and BARF-1 in EBV 
 Apparently, several restricted forms of EBV la-
tency  occur  in  the  EBV-carrying  malignancies,  and 
modulation  of  LMP1  expression  differs  greatly  de-
pending on the latency form. In B cells with type III 
latency, the EBV genome expresses six nuclear anti-
gens (EBNA-1 to -6) and three latent membrane pro-
teins (LMP1, -2A, -2B). EBNA-2 and -5 are responsible 
for  LMP1  expression.  In  type  II  latency,  which  is 
mainly  found  in  Hodgkin  lymphoma,  T-  and 
NK-lymphoma, and NPC, the EBV genome expresses 
only EBNA-1 and LMPs. The expression of LMP1 is 
induced  by  IL-10  [118]  and  IL-21  [119].  In  Burkitt Int. J. Biol. Sci. 2010, 6 
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lymphoma, which has type I latency, only EBNA-1 is 
expressed. 
 The  oncoprotein  LMP1  of  EBV  is  a  62-kD 
integral  membrane  protein  of  386  aa  residues  that 
consists of a short cytoplasmic N-terminus of 24 aa, 
six transmembrane domains of 186 aa, and a cytop-
lasmic C-terminus of 200 aa (Fig. 5A) [120]. EBV LMP1 
is essential for the immortalization and transforma-
tion of human B cells, but its oncogenic activity can be 
downregulated by a truncated LMP1 (258 aa) [121]. 
LMP1  without  a  ligand  drives  proliferation  of 
EBV-infected B cells by signaling within the B cells 
similar to the signaling of the cellular CD40 receptor 
[122]:  both  activate  NF-κB,  AP-1,  Stat-1,  CD83,  and 
CD95 by associating with molecules such as TRAFs 
and  JAK3.  LMP1's  signaling,  however,  differs  fun-
damentally from that of CD40, because LMP1 regu-
lates  these  signaling  pathways  without  itself  being 
regulated by a ligand, as CD40 is. LMP1 levels vary in 
cells  of  clonal  populations  by  more  than  100-fold, 
which leads to multiple distinct activities of the on-
coprotein.  When  expressed  at  intermediate  levels, 
LMP1 signals through NF-κB to promote cell prolife-
ration. When expressed at high levels, LMP1 inhibits 
general  protein  synthesis by  inducing phosphoryla-
tion of eIF2α via activation of PERK kinase, leading to 
upregulation  of  activating  transcription  factor  4 
(ATF4)  expression,  which  in  turn  transactivates 
LMP1's own promoter [18]. LMP1 activation leads to 
overexpression  of  antiapoptotic  molecules,  such  as 
Bcl-2, Mcl-1, and Bcl-2–related protein A1 (Bfl-1) [123] 
and  blocks  p53-mediated  apoptosis  through  the  in-
duction of the A20 gene [124]. Complementary to its 
proliferative  function,  LMP1  inhibits  proapoptotic 
factors  such  as  Bax  [125]  and  downregulates  TCL1 
oncogene through miR-29b [126]. 
 
 
Figure 5. Schematic structures of EBV LMP1 protein and its RNAs. A. Full-length LMP1 protein. Both the N-terminal and 
C-terminal cytoplasmic domains are white boxes and the transmembrane domain is a shaded box. Protein-protein inte-
racting motifs are indicated as colored ovals, and a 30-nt deletion (del.) or duplication (dupl.) region often seen in naso-
pharyngeal carcinomas or B cells is underlined. TRAF, TNFR-associated factor; TRADD, TNFR-associated death domain 
protein; JAK3, Janus kinase 3. B. Schematic structure of LMP1 mRNAs. Promoters driving the expression of LMP1 and 
truncated LMP1 are shown relative to the EBV genome. Black dots indicate the first AUG on each transcript that is used for 
translation initiation.  Int. J. Biol. Sci. 2010, 6 
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 The  LMP1  (BNLF1)  gene  contains  three  exons 
and two introns that are located within the BamHI-N 
region of the EBV genome [120,127]. Two ORFs have 
been  identified  based  on  nucleotide  sequences  and 
mRNA  mapping  of  EBV  B95-8  [128].  A  transcript 
starting from the ED-L1 promoter, which is located 
upstream of the first exon, encodes full-length LMP1 
(386 amino acids; Fig. 5B) from the first ORF that is 
abundantly  expressed  in  lymphoblastoid  cell  lines. 
There is no alternative RNA splice site in either of its 
two  introns.  Another  transcript  starting  from  the 
ED-L1A promoter, which is located within the first 
intron  of  the  LMP1  gene,  encodes  the  second  ORF 
(Fig. 5B). The translation initiation site of this second 
ORF is methionine-129 of full-length LMP1 [128], and 
the ORF thus encodes an amino-terminally truncated 
form of the LMP1 protein. The truncated LMP1 (258 
amino  acids)  consists  of  the  fifth  and  sixth  trans-
membrane  domains  and  the  cytoplasmic  carboxy 
terminus of full-length LMP1. 
 Although  the  B95-8  cell  line,  an  in  vi-
tro–immortalized  lymphoblastoid  cell  line,  was  in-
itially used to characterize truncated LMP1, a number 
of studies demonstrated that expression of truncated 
LMP1  was  specifically  upregulated  during  the  lytic 
phase  of  viral  replication.  Therefore,  the  truncated 
form  of  LMP1  is  frequently  referred  to  as  lytic 
LMP1[129]. In contrast to full-length LMP1, truncated 
LMP1 does not transform rodent cells [130] or alter 
the phenotypes of human B lymphocytes [131]. The 
biological activity of truncated LMP1 is its ability to 
negatively  regulate  LMP1  signaling  pathways  [132] 
and LMP-1–mediated oncogenesis [121]. 
 The  BARF1  gene  is  located  in  the  BamHI-A 
fragment of the EBV genome and has potential onco-
genic  activity.  The  BARF1  gene  encodes  a  31-kDa 
early protein, but can be expressed as a “latent” pro-
tein,  in  particular  in  NPC  biopsy  samples  [21,133]. 
BARF1  induces  malignant  transformation  of  rodent 
fibroblasts  [22],  enhances  the  tumorigenicity  of 
EBV-negative  Burkitt  lymphoma–derived  cell  lines 
[134], and immortalizes primary epithelial cells [135]. 
BARF1-rEBV–infected  NPC  cells  are  tumorigenic  in 
nude  mice  [23].  A  54-amino-acid  region  of  the 
N-terminus, which is capable of activating expression 
of the antiapoptotic protein bcl-2, is essential for the 
transforming  activity  [136].  B  cells  with  BARF1  ex-
pression exhibit increased levels of c-myc, CD23, and 
CD2. BARF1 can also be secreted as a soluble receptor 
for human colony-stimulating factor [134,137]. In this 
form, it regulates the immune response by inhibiting 
interferon-α secretion from mononuclear cells and is 
detectable, along with LMP1, in the serum and saliva 
of patients with NPC [138]. The secreted BARF1 and 
LMP1 are mitogenic.  
Tax in HTLV 
 The  HTLV-1  Tax  protein  is  a  40-kD  nuclear 
phosphoprotein that consists of 353 aa residues. To 
distinguish it from the HTLV-2 Tax protein (p37tax or 
Tax2), the HTLV-1 Tax is also called p40tax or Tax1. 
Tax1 and Tax2 share many characteristic properties, 
including  in  vitro  immortalization  of  lymphocytes. 
HTLV-1 Tax is a transcriptional activator of the viral 
promoter and has been implicated in initiating trans-
formation events leading to the development of adult 
T-cell leukemia, but it is not needed to maintain cell 
transformation, and the tumor cells from adult T-cell 
leukemia  do  not  express  detectable  levels  of  Tax 
[139,140].  This  makes  HTLV-1  Tax  different  from 
other cancer viruses, in which a continuous expres-
sion of viral oncogene is necessary for maintenance of 
transformation. However, it is clear that HTLV-1 Tax 
is  oncogenic,  because  in  all  reported  studies  Tax 
transgenic mice were vulnerable to developing vari-
ous tumors [141-143]. The emerging concept [144] is 
that  Tax  is  required  to  initiate  transformation,  but 
viral HBZ protein [145,146] and/or aberrant cellular 
microRNA expression [147,148] appear to be needed 
to  maintain  adult  T-cell  leukemia  when  Tax  is  no 
longer expressed.  
 HTLV-1 Tax is a pleiotropic transcription factor 
that modulates transcription of many cellular genes 
through direct interactions with transcriptional acti-
vators,  basal  transcription  factors,  and  proteins  in-
volved in chromatin remodeling as well as cell cycle 
progression [149]. Its role in transcription and regula-
tion of cell cycle progression are further supported by 
its direct presence in nuclear transcription hot spots 
and nuclear speckles containing SC35 [150] as well as 
by its direct association with many cell cycle regula-
tors [151]. Tax also associates with proteins involved 
in  post-transcriptional  control  of  mRNAs  to further 
modulate gene expression. Thus, Tax plays an essen-
tial role in viral and cellular transcription as well as in 
cell transformation and oncogenicity.  Structurally, 
HTLV-1 Tax bears multiple protein-binding domains 
(Fig. 6A), as reviewed recently [152]. Its N-terminal 
region has a zinc finger motif that is responsible for its 
interaction  with  various  transcription  factors 
[153-155]. This region overlaps with an NLS. Muta-
tions within this zinc finger affect Tax-mediated CREB 
transactivation  as  well  as  subcellular  localization 
[156].  
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Figure 6. Schematic structure of the HTLV-1 Tax protein and production of Tax mRNA by alternative RNA splicing. A. 
Functional regions of HTLV-1 Tax protein. NLS, nuclear localization signal; Zn, zinc finger; LZR, leucine-zipper-like region; 
NES, nuclear export signal; GLM, Golgi localization motif; SM, secretion motif; PDZ, PDZ-binding domain. B. HTLV-1 Tax 
expression by alternative RNA splicing. The HTLV-1 genome structure is shown at the top of the panel, with nine species of Int. J. Biol. Sci. 2010, 6 
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mRNAs diagramed below. Boxes above RNA exons (solid lines) show an ORF in each spliced mRNA that is used for 
translation of an individual accessory protein. Introns and splicing directions for each mRNA species are indicated by the 
dotted lines. Six accessory proteins expressed by alternative RNA splicing all originate from a single pre-mRNA transcribed 
from the 5' LTR, and their cellular localizations are shown at the right. In addition, HTLV-1 basic leucine zipper factor (HBZ) 
minus-strand RNA is transcribed from the 3' LTR in an antisense fashion [271,272], and its encoded protein is a nuclear 
protein [273], as shown at the right. Panel B is modified from reference [151] with permission.  
 
 
The middle part of Tax bears a region for dime-
rization  that  also  overlaps  with  two  leucine  zip-
per–like  motifs  and  a  nuclear  export  sequence 
[157-159]. Substitutions within the first leucine zipper 
affect  Tax  interactions  with  NF-κB  and  PP2A 
[160,161].  The C-terminal region of Tax  contains an 
activation domain [162], a Golgi localization and se-
cretion motif [163], an Rb-binding sequence [164], and 
a PDZ-binding domain [165].  
CONTROL OF VIRAL ONCOGENE 
EXPRESSION BY ALTERNATIVE RNA 
SPLICING  
Regulation of HPV16 and HPV18 E6 and E7 ex-
pression by alternative RNA splicing 
 The E6 and E7 genes are positioned side by side 
at the beginning of papillomavirus genome. The ex-
pression strategy of oncogenic E6 and E7 differs from 
that of non-oncogenic E6 and E7. In oncogenic HPV16 
and  HPV18, the two genes are expressed as a  bici-
stronic  pre-mRNA  from  a  single  promoter  imme-
diately  upstream  of  the  E6  ORF.  In  nononcogenic 
HPV6  and  HPV11,  the  genes  are  expressed  indivi-
dually  from  two  separate  promoters.  Another  noti-
ceable feature is that oncogenic E6 genes contain an 
intron,  whereas  non-oncogenic  E6  genes  do  not. 
Consequently,  a  spliced  E6  ORF  is  predominant  in 
oncogenic  E6  mRNAs,  but  does  not  exist  in 
non-oncogenic  E6  mRNAs  (Table  2),  suggesting  an 
important role of the E6 splicing in viral oncogenesis. 
Of note, the same promoter that drives oncogenic E6 
and E7 expression is also responsible for almost all 
early  gene  expression,  and  the  resulting  early  tran-
scripts  are  polyadenylated  by  using  the  same  early 
poly(A)  signal  [166,167].  Therefore,  these  early  pri-
mary  transcripts  are  all  bicistronic  or  polycistronic, 
and each has two or more ORFs and contains three 
exons and two introns [167].  
 In HPV16, intron 1 and intron 2 of an E6E7 pri-
mary transcript each contain three alternative 3' splice 
sites which can  be selected for RNA splicing in vi-
rus-infected cells, leading to the production of at least 
14 species of mRNA transcripts with various coding 
potential [167]. Intron 1 of an HPV18 E6E7 primary 
transcript has a single 3' splice site. Because intron 1 
and  intron  2  are  positioned,  respectively,  in  the  E6 
ORF and E1 ORF, retention of intron 1 during RNA 
splicing is necessary for E6  expression, whereas re-
tention of intron 2 is needed for E1 production. E1 
functions as a viral DNA helicase essential for viral 
DNA  replication  [168].  Splicing  of  either  intron  de-
stroys the coding of E6 or E1. Mechanistically, there 
are  only  shameful  data  currently  available  on  how 
each intron could escape recognition by the cellular 
splicing  machinery  in  order  to  produce  these  two 
important viral proteins. The cap-binding complex at 
the RNA 5' end was initially found to promotes the 
splicing of intron 1 of HPV16 E6E7 transcripts, but the 
enhanced intron 1 splicing by the cap-binding com-
plex can be restrained by the distance of intron 1 from 
its RNA 5' cap [169]. Under natural conditions, cellu-
lar epithelial growth factor (EGF) pathway regulates 
the intron 1 splicing of HPV16 E6E7 transcripts via 
Erk1/2 activation [170]. It is possible that the onco-
genic HPVs retain an intron as needed by interfering 
with the action of the splicing machinery using their 
own proteins. The findings that both HPV16 E2 and 
E6 act as RNA-binding proteins that suppress splicing 
[83] and viral E5 regulation of EGFR expression [171] 
may help us to understand this striking phenomenon. 
 Splicing of intron 1 in the HPV16 and HPV18 
E6E7 pre-mRNAs is highly efficient, and the majority 
of the transcripts in cervical cancer tissues and cer-
vical  cancer–derived  cell  lines  are  E6*I,  a  spliced 
transcript  without  intron  1.  Why  then  is  efficient 
splicing  of  intron  1  in  the  HPV16  or  HPV18  E6E7 
pre-mRNA needed for viral gene expression, since the 
splicing harms E6 expression? It has been proposed 
that splicing of intron 1 in 16E6E7 pre-mRNA might 
benefit E7 expression [53,172], because the space be-
tween  the  termination  of  E6  translation  and  the 
re-initiation of E7 in an intron 1–containing 16E6E7 
mRNA  is  limited,  with  only  two  nucleotides  (nts) 
between them. This limited space between the E6 ORF 
and the E7 ORF would not give enough room or time 
for a scanning ribosome to release all of its termina-
tion  components  and  to  reload  all  of  the  necessary 
translation components to re-initiate translation of the 
E7  ORF  on  the  same  bicistronic  mRNA  [173].  This 
hypothesis  regarding  E7  expression  was  recently 
proven  in  various  experiments  in  my  laboratory Int. J. Biol. Sci. 2010, 6 
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[169,174]. Splicing of intron 1 creates a frameshift, and 
the  resulting  E6*I  mRNA  obtains  a  pre-termination 
codon immediately downstream of the splice junction 
and, accordingly, creates enough space for the trans-
lation  termination  of  E6*I  and  re-initiation  of  E7 
translation by a scanning ribosome[175]. Mutation of 
the intron 1 5' splice site to prevent RNA splicing or 
narrowing  the space between the E6*I ORF and  E7 
ORF from 145 nts to 2 nts significantly decreases E7 
expression, demonstrating that E7 is translated from 
the spliced isoforms of 16E6E7 mRNAs, and splicing 
of intron 1 from the E6 coding region is essential for 
the  production  of  the  viral  oncoprotein  E7  (Fig.  7) 
[169,174].  
 
Table 2. E6 splicing and carcinogenesis of HPVs. 
 
 
 
 
 
 
 
Figure 7. Intron 1 splicing in the E6 ORF in HPV16 or HPV18 E6E7 pre-mRNA is essential for E7 production. The HPV16 
or HPV18 E6E7 pre-mRNA contains three exons (colored boxes) and two introns (lines). The majority of the E6E7 RNA 
species in cervical cancer tissues and cervical cancer–derived cell lines are fully spliced E6*I mRNAs, which are utilized for E7 
translation. However, the presence of a minimal amount of partially spliced E6 with retention of intron 1 has been detected 
in cervical cancer tissues and cervical cancer–derived cell lines. This RNA species contains an entire E6 ORF and functions 
as an E6 mRNA for E6 translation [174]. 
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Regulation of adenovirus E1A and E1B expres-
sion by alternative RNA splicing 
 Adenovirus E1A pre-mRNA contains three ex-
ons and two introns. The suboptimal feature of E1A 
intron 1  makes it a  minor intron, and its usage for 
RNA splicing occurs mainly late in infection. Intron 2, 
which has two alternative 5' splice sites, is a major 
intron of E1A pre-mRNA and is used constitutively 
for RNA splicing in every species of E1A mRNA, both 
early and late in virus infection. Through alternative 
RNA splicing of intron 2, and inclusion or exclusion of 
intron  1,  the  adenovirus  E1A  pre-mRNA  generates 
five different mRNAs, designated 13S, 12S, 11S, 10S, 
and 9S mRNA according to their sedimentation coef-
ficients [176].These mRNAs give rise to five distinct 
proteins of 289 aa residues (13S mRNA), 243 aa (12S 
mRNA), 217 aa (11S mRNA), 171 aa (10S mRNA), and 
55  aa  (9S  mRNA)[177]  (Fig.  2B).  The  13S  and  12S 
mRNAs  are  the  two  major  spliced  mRNAs  during 
early virus infection, and their protein products share 
the same N- and C-terminal aa sequences but differ in 
the  CR3  region,  which  is  unique  to  the  E1A-289R 
protein. The 9S mRNA accumulates to relatively high 
levels late in virus infection, at which time the 11S and 
10S mRNAs are only minimally expressed [178].  
 In  the  past  two  decades,  a  number  of  studies 
have shown that individual SR and non-SR proteins 
play roles in the selection of each alternative 5' splice 
site and in the shift from 13S to 9S RNA production. 
One interesting finding is that the 13S-to-9S transition 
can be triggered through titration of the SR proteins 
9G8, SC35, and ASF/SF2 by major-late transcripts that 
accumulate  in  nuclei  late  in  the  infection  [179]. 
ASF/SF2  was  the  first  of  the  SR  proteins  found  to 
relate to the selection of the 13S 5' splice site, but its 
role in this 5' splice site selection can be antagonized 
by overexpressed hnRNA A1 [180,181], SRrp35, and 
SRrp40  [182].  ASF/SF2  RNA-binding  domain  2  sti-
mulates splicing of the 13S 5' splice site and simulta-
neously  represses  12S  5'  splice  site  splicing  [183]. 
SRp40 [184], SRp54 [185], TLS [186], and RBM4 [187] 
were found to preferentially activate the 9S 5' splice 
site, but SRp75 enhances the recognition of the 12S 
5'splice site [188]. However, lack of a specific binding 
site upstream of the 13S and 9S 5' splice sites for these 
proteins suggests that individual splicing regulators 
of the 5' splice site selection might function in an RNA 
sequence–independent  manner  (Fig.  2B).  Identifica-
tion of a purine-rich ESE (named bidirectional splic-
ing enhancer, BSE) located immediately upstream of 
the 12S 5' splice site, and demonstration that such an 
ESE is involved in selection of the 12S 5' splice site and 
intron 1 3' splice site through binding to the SR pro-
teins 9G8 and ASF/SF2, suggests that at least one of 
the 5' splice site and 3' splice site in the adenovirus 
type 2 (ad2) E1A pre-mRNA is preferentially selected 
in  an  ESE-dependent  manner  [189].  The  binding  of 
9G8 to the ESE strongly activates the selection of the 
12S  5'  splice  site,  whereas  the  binding  of  ASF/SF2 
stimulates the usage of the intron 1 3' splice site [189]. 
Exon  definition  also  plays a  role  in  stimulating  the 
intron 1 3' splice site usage for 9S mRNA production. 
Of note, the 13S 5' splice site but not the 12S 5'splice 
site  has  been  described  as  activating  the  upstream 
intron 1 3' splice site, crossing over exon 2 [190].  
 The  E1B  gene  of  adenovirus  encodes  a 
pre-mRNA with three exons and two introns (Fig. 3B). 
Although the E1B intron 1 is suboptimal and large in 
size, it contains two alternative 3' splice sites. E1B in-
tron 2 is constitutively spliced and small in size, but is 
used in RNA splicing for production of every species 
of the E1B mRNA. Through alternative RNA splicing, 
the primary transcript from the E1B gene produces at 
least four additional spliced forms of E1B mRNAs of 
2.28, 1.26, 1.31, and 1.02 kb to translate five distinct 
E1B  proteins  of  496R  (E1B-55K),  176R  (E1B-19K), 
156R, 93R, and 84R (Fig. 3B). E1B-19K and E1B-55K 
are created from the same 2.28-kb transcript but have 
two  different  initiation  codons  and  different  ORFs 
[109], and the two proteins are therefore not related. 
However, E1B-55K shares the same N-terminal 79 aa 
residues  with  E1B-156R,  E1B-93R,  and  E1B-84R 
translated from exon 1, and the same C-terminal 77 aa 
residues with E1B-156R from exon 2 [191]. E1B-93 and 
E1B-84 have unique C-termini due  to usage of  two 
alternative 3' splice sites and termination at two dif-
ferent stop codons. 
 Production of the different E1B mRNAs during 
infection  is  regulated  over  time.  While  the  2.28-kb 
form is the main form produced early in infection, the 
proportion  of  the  shorter  spliced  mRNAs  increases 
over time, and the E1B-84R mRNA becomes predo-
minant in the late phase. The splicing mechanism of 
E1B pre-mRNA has been investigated much less tho-
roughly  than  the  splicing  of  E1A  pre-mRNA,  and 
there is no information on whether RNA cis-elements 
or splicing factors are involved in the regulation of 
E1B alternative RNA splicing. 
Regulation of polyomaviral T antigen expression 
by alternative RNA splicing 
 The primary transcript of polyomaviral T anti-
gen has two exons and one intron. The T antigen in-
tron  contains  two  alternative  5'  splice  sites  and  its 
alternative  usage  during  RNA  splicing  leads  to  the Int. J. Biol. Sci. 2010, 6 
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production of two spliced mRNAs, LT and st. In this 
regard, the st intron is relatively weak because of its 
limiting size and utilizes a different branch point from 
LT  for  its  splicing  [192],  giving  the  LT  splicing  a 
competitive advantage relative to st splicing. Whether 
the two alternative 5' splice sites are regulated by an 
exonic  or  intronic  splicing  enhancer  or  silencer  re-
mains to be identified. Historically, investigation into 
why the ratio of st to LT mRNAs is much greater in 
293  cells  than  in  HeLa  cells  led  to  discovery  of 
ASF/SF2 as a splicing factor that promotes st 5' splice 
site  splicing  [180,193].  In  contrast,  overexpressed 
ASF/SF2 inhibits the selection of the st 5' splice site, 
and the overexpression of SC35 blocks splicing of both 
LT and st 5' splice sites and promotes nuclear accu-
mulation of the unspliced pre-mRNA (Fig. 4B) [194]. 
There is a minor intron within exon 2 of SV40 LT that 
can be spliced from LT mRNA, leading to production 
of a 17-kDa T antigen consisting of 135 aa residues, of 
which  131  correspond  to  the  N-terminus  of  LT 
[195,196]. This transcript is detectable in MCC tumors 
in addition to MCV LT and st transcripts [27].  
Regulation of HTLV-1 Tax expression by alter-
native RNA splicing   
 HTLV-1  Tax  mRNA  is  derived  by  alternative 
RNA  splicing  from  a  common  pre-mRNA  whose 
transcription  is  initiated  from  the  5'  LTR  of  the 
HTLV-1 genome (Fig. 6B). Thus, Tax mRNA contains 
a common 5' leader exon as its 5' UTR, as seen in all 
other spliced HTLV-1 RNA species, and a Tax ORF 
that spans exon 2 and exon 3. To produce Tax mRNA, 
the pre-mRNA needs to be double-spliced and pre-
cisely controlled, as the pre-mRNA has multiple weak 
3' splice sites that can be alternatively utilized during 
RNA  splicing  to  generate  several  other  species  of 
mRNAs.  Unfortunately,  we  know  nothing  today 
about how each splice site is selected and what con-
trols the selection of individual 3' splice sites. 
VIRAL NONCODING RNAs AND micro-
RNAs IN VIRAL ONCOGENESIS 
Viral noncoding RNAs in viral oncogenesis 
 Tumor  viruses  encode  several  abundant  RNA 
molecules  without  coding  function.  These  include 
EBV  EBER  RNAs  [197,198],  KSHV  PAN  RNA  (po-
lyadenylated nuclear RNA) [199,200] and herpesvirus 
saimiri  small  nuclear  RNAs  [201,202].  They  are  all 
produced from tumor cells with latent or lytic tumor 
virus infection and are different in size from viral mi-
croRNAs.  The  functions  of  these  viral  noncoding 
RNAs  remain  to  be  understood.  There  is  no  direct 
correlation between expression of these RNA mole-
cules during virus transformation and tumorigenesis. 
However,  recent  studies  show  these  noncoding 
RNAs,  in  particular  EBV  EBERs,  might  have  some 
functions related to virus latency, cell survival, and 
oncogenic potential. It is possible that tumor viruses 
might  utilize  these  noncoding  RNAs  to  manipulate 
host-cell gene expression by down-regulation of host 
microRNAs as reported in herpesvirus saimiri [203].  
 EBV-encoded EBER RNA molecules that might 
contribute to oncogenesis have been reported [204]. 
EBER-1 (166 nts) and EBER-2 (172 nts) are two non-
polyadenylated  nuclear  RNAs  transcribed  by  the 
RNA polymerase III system [198,205]. Both are com-
plexed  with  cellular  La  protein  and  have  extensive 
primary sequence similarity to adenovirus VA1 and 
VA2 [206] and cellular U6 small RNA [198]. EBERs 
may  play  a  role  in  the  maintenance  of  malignant 
phenotypes  of  Burkitt  lymphoma  cells  by  enabling 
clonability in soft agar; tumorigenicity in immunode-
ficient  mice;  upregulated  expression  of  bcl-2  onco-
protein; resistance to apoptosis [207]; and induction of 
IL-9, IL-10, and IGF [208-210]. EBERs confer resistance 
to interferon-α and Fas-mediated apoptosis by inhi-
biting double-stranded RNA–activated protein kinase 
R through direct binding [211,212].    
Viral microRNAs in viral oncogenesis 
 MicroRNAs  are  regulatory,  noncoding  RNAs 
about 21-23 nucleotides in length and have large-scale 
effects on the expression of a variety of genes at the 
post-transcriptional level. Through base-pairing with 
its targeted mRNAs, a microRNA induces RNA de-
gradation or translational suppression of the targeted 
transcripts [213,214]. All DNA tumor viruses except 
human  papillomaviruses  encode  viral  microRNAs. 
EBV  encodes  up  to  25  viral  microRNAs  precusors 
from  two  clusters  in  the  EBV  genome  [215-217]. 
Fourteen of the 20 BART (BamHI-A rightward tran-
scripts)-derived microRNAs are produced from BART 
introns prior to completion of the RNA splicing and 
are  highly  expressed  in  latently  infected  epithelial 
cells, but at much lower levels in B cells. In contrast, 
three  BHRF1  (Bam  HI  fragment  H  rightward  open 
reading frame 1) miRNAs expressed within introns of 
EBNA transcripts are found at high levels in B cells 
with stage III latency but are essentially undetectable 
in B cells or epithelial cells with stage I or II latency 
[216,218,219]. It is true that all EBV miRNAs from the 
BART region are expressed in NPC tissues, whereas 
EBV miRNAs from the BHRF1 region are not found 
[220-222]. KSHV encodes 12 viral microRNA precur-
sors,  most  of  which  are  from  a  large  intron  of  the 
KSHV  latency-associated  region,  where  KSHV 
LANA, vCyclin, vFLIP, and Kaposin are transcribed 
[223,224].  Like  EBV  microRNAs,  KSHV  microRNAs Int. J. Biol. Sci. 2010, 6 
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are also expressed in B cells with latent KSHV infec-
tion. Among the polyomaviruses, MCV encodes one, 
BK virus generates four, and SV40 and JC virus each 
produce two microRNAs. All of these microRNAs are 
produced  late  during  virus  infection  [225-227]  and 
play a role in degradation of viral early mRNAs. The 
SV40 microRNAs confer resistance of virus-infected 
cells to lysis by cytotoxic T cells [225]. Human adeno-
virus probably produces a microRNA [224]. To date, 
there  has  been  no  report  about  the  production  of 
HPV-derived microRNAs [228,229].  
 Viral microRNAs may modulate tumorigenesis 
through various mechanisms during tumor virus in-
fection.  For  example,  recent  studies  show  that  EBV 
BHRF1-3  microRNAs  target  chemokine 
CXCL-11/I-TAC for its suppression, which may serve 
as  an  immunomodulatory  mechanism  in 
AIDS-related  diffuse  large  B-cell  lymphomas  [230]. 
EBV miR-BART2 downregulates viral DNA polyme-
rase BALF5 and inhibits the transition from latent to 
lytic viral replication [231]. EBV miR-BART5 inhibits 
the  expression  of  the  cellular  protein  PUMA  (p53 
upregulated modulator of apoptosis) to promote host 
cell survival and the establishment of latent EBV in-
fection [232]. EBV miR-BART1, -16, and -17 reduce the 
expression of EBV LMP1 to prevent its overexpres-
sion, which would lead to inhibition of cell prolifera-
tion and an increased susceptibility to apoptotic sti-
muli  [233].  By  systematically  introduction  of  muta-
tions in EBV's precursor miRNA  transcripts to pre-
vent  their  subsequent  processing  into  mature  viral 
miRNAs,  a  recent  study  shows  that  viral  miRNAs 
from the BHRF1 locus inhibit apoptosis and favor cell 
cycle progression and proliferation during the early 
phase of infected human primary B cells [234].  
 KSHV  miR-K12-11  shares  sequence  identity 
with cellular miR-155 in the seed region, which con-
fers much of the target specificity, and has the poten-
tial  to  regulate  multiple  transcripts,  in  particular 
BACH-1 (BTB and CNC homology 1, a transcription 
factor), via the same binding sites utilized by the host 
miR-155 [235,236]. KSHV miR-K12–1, miR-K12-3-3p, 
miR-K12-6-3p, and miR-K12–11 reduce the expression 
of THBS1 (thrombospondin 1) by interaction with the 
THBS1  3'  UTR.  THBS1  functions  in  cell–cell  and 
cell–matrix adhesion and possesses both antiprolifer-
ative and anti-angiogenic activity [237]. More studies 
from  recent  reports  indicate  miR-K12-5,  miR-K12-9 
and  miR-K12-10  repression  of  Bcl-2-associated  tran-
scription factor 1, an apoptosis-inducing factor [238], 
miR-K12-3 reduction of LRRC8D (leucine rich repeat 
containing 8 family, member D), a leucin-rich type III 
transmembrane protein involved in proliferation and 
activation  of  lymphocytes,  NHP2L1  (non-histone 
chromosome protein 2-like 1) [239], and a transcrip-
tion  factor  NFIB  [240],  miR-K12-1  inhibition  of  p21 
[241]  and  NFκB  inhibitor  IκBα  [242],  miR-K12-4-3p 
suppression of GEMIN8 [239], miR-K12-10a reduction 
of TWEAKR [243], miR-K12–1, -6, and -11 decrease of 
MAF  (musculoaponeurotic  fibrosarcoma  oncogene 
homolog)  [244],  K12-4-5p  targeting  retinoblastoma 
(Rb)-like  protein  2  (Rbl2)  and  miR-K12-5  and 
-9*suppressing  ORF50  mRNA  [245,246].  Together, 
these data suggest mutiple roles for these viral mi-
croRNAs in pathogenesis and  potentially  tumorige-
nesis in the KSHV-infected host.  
VIRAL ONCOPROTEINS AND CELLULAR 
microRNAs 
 Although much has been learned about the ab-
errant  expression  of  cellular  microRNAs  in  various 
tumor virus–induced cancers, the mechanism of this 
aberrant  expression  remains  largely  unknown. 
However, several exciting reports suggest that viral 
oncoproteins may play an important role in this ab-
errant  regulation  of  cellular  microRNA  expression, 
including those oncogenic or tumor suppressive mi-
croRNAs.  
 EBV  oncoprotein  LMP1  dysregulates  the  ex-
pression of several cellular miRNAs. LMP1 induces 
miR-146a predominantly through two NF-κB–binding 
sites in the miR-146a promoter [247]. This observation 
was  verified in a separate study  showing that EBV 
LMP1  activates  the  miR-146a  promoter  but  not  a 
promoter  with  a  mutation  of  the  NF-κB  response 
elements [248]. EBV LMP1 also induces the produc-
tion of the BIC (B-cell integration cluster) precursor 
RNA of cellular miR-155, which is highly expressed in 
various B-cell lymphomas and may contribute to EBV 
immortalization  of  B  cells  [249,250].  Recent  studies 
have confirmed that LMP1 signals through NF-κB to 
transactivate miR-155 expression [251] to immortalize 
B-cells [252]. 
 Tumor-suppressive miR-34a is transactivated by 
the binding of p53 to a perfect p53-binding site in the 
miR-34a  regulatory  region.  My  laboratory  recently 
observed [253] that expression of miR-34a is reduced 
in cervical cancer tissues and cervical cancer–derived 
cell  lines  containing  oncogenic  HPVs  because  the 
HPV oncoprotein E6 destabilizes the tumor suppres-
sor p53. The reduction of miR-34a expression in or-
ganotypic tissues derived from HPV-containing pri-
mary  human  keratinocytes  correlates  with  the  ex-
pression of viral E6. Knockdown of viral E6 expres-
sion in HPV16+ and HPV18+ cervical cancer cell lines 
by siRNAs leads to increased expression of p53 and 
miR-34a and a substantial retardation of cell growth. 
Our study has thus provided new insights into me-Int. J. Biol. Sci. 2010, 6 
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chanisms by which high-risk HPVs contribute to the 
development  of  cervical  cancer  [253].  Reduced 
miR-34a  expression  also  occurs  in  normal  cervical 
tissues and cervical lesions with high-risk HPV infec-
tions [254]. In addition, two other reports show that 
high-risk HPV E6 downregulates miR-218 [255] and 
E7  reduces  miR-203  expression  upon  keratinocyte 
differentiation [256], but the mechanisms of how these 
regulations take place remain unknown.  
 HTLV-1 Tax is oncogenic in transgenic mice and 
is  required  for  immortalization  of  human 
T-lymphocytes and transformation of rodent fibrob-
last [149,257]. Recent studies indicate that Tax trans-
activates miR-146a expression by binding to a single 
NFκB site in the miR-146a promoter proximal to the 
transcription start site [148]. Tax may also transacti-
vate  miR-130b  expression  by  regulating  the  expres-
sion of transcription factors most likely required for 
miR-130b promoter to function [147].  
REMARKS 
 It has been almost a century since the discovery 
of  virus-induced  cancers.  Studies  on  tumor-causing 
viruses  have  led  to  many  landmark  breakthroughs 
that  have  revolutionized  cell  biology  and  the  prin-
ciples of medicine, helped to establish virology as a 
discipline, and paved the way for most of the subse-
quent advances and ideas on the molecular basis of 
viral carcinogenesis. These milestone discoveries in-
clude the identification of RNA-dependent DNA po-
lymerase (reverse transcriptase) in Rous sarcoma vi-
rus by Howard Temin and David Baltimore [258,259], 
viral oncogenes and their cellular counterparts (pro-
to-oncogenes)  from  Rous  sarcoma  virus  by  Harold 
Varmus  and  Michael  Bishop  [260,261],  and  RNA 
splicing in adenovirus-2 by Philip Sharp and Richard 
Roberts [262,263]. 
 Viral strategies for manipulating the expression 
of  cellular  genes  to  enhance  viral  persistence,  viral 
latency, and survival of infected cells have provided 
numerous clues to the mechanisms of gene expression 
and their dysregulation during tumor development. 
These  functions  are  mainly  undertaken  by  vi-
rus-encoded oncogenes, which are present in virtually 
all well-characterized tumor viruses except the hepa-
titis C virus. The fact that all characterized viral on-
coproteins  are  “sticky”  and  interact  with  cellular 
proteins in infected cells makes each of them multi-
functional and essential for cell immortalization and 
transformation. By interacting with several dozens or 
even hundreds of cellular factors, viral oncoproteins 
from  different  tumor  viruses  eventually  end  up  in 
apparently similar scenarios of viral carcinogenesis by 
targeting  cellular  tumor  suppressors,  deregulating 
signal transduction pathways, redirecting gene tran-
scription, and/or stimulating anti-apoptotic programs 
in the host. In the past two decades, the study of can-
cer  biology  has  been  driven  by  the  dynamic  net-
working capacity of individual viral oncoproteins.  
 RNA splicing plays an important role in regu-
lating  viral  oncogene  expression  and is  highly  con-
served  among  tumor  viruses.  Through  alternative 
RNA splicing, several species of mRNAs can be de-
rived from a primary transcript of a single viral on-
cogene to encode different truncated proteins or dif-
ferent  oncoproteins.  Although  various  studies  over 
the  years  have  shown  that  the  levels  and  status  of 
individual  cellular  splicing  factors  in  virus-infected 
cells modulate alternative splicing of viral oncogene 
transcripts,  a  clear  picture  of  how  this  modulation 
might  take  place  during  viral  oncogene  expression 
has not yet emerged. Because viral RNA transcripts 
are not naked in the cells and the movement of dif-
ferent sets of RNA-binding proteins on and off a par-
ticular RNA molecule is dynamic, it will be very in-
teresting  to  know  how  the  selection  of  alternative 
splice sites in an RNA is precisely defined and trig-
gered. In the case of an HPV16 or HPV18 E6E7 bici-
stronic  transcript,  retention  of  the  first  intron  is 
needed to express E6, but splicing of this intron pro-
motes  E7  translation  initiation  to  produce  E7[174]. 
What is required for the decision to splice this intron 
or  not,  resulting  in  the  expression  of  two  different 
oncoproteins from the same transcript, and when this 
decision  occurs  are  intriguing  questions.  A  recent 
finding of EGF pathway that might be involved in this 
regulation is fascinating [170]. Thus, investigation into 
these questions will not only help to resolve this puz-
zle in tumor virology, but will also shed some light on 
complex biology as a whole. 
 Noncoding  RNAs,  including  microRNAs  and 
endogenous siRNAs, have profound roles in the reg-
ulation  of  gene  expression  [264-268].  During  latent 
virus infection, DNA tumor viruses, except papillo-
maviruses, generate abundant noncoding RNAs. Al-
though we know very little at the present why viruses 
produce them and what their functions are, the pro-
duction of these noncoding RNAs by these groups of 
tumor viruses means that the function of the tumor 
virus genome has been highly conserved during virus 
evolution. Noncoding RNAs are not a consequence of 
virus latency; rather, their function might be neces-
sary for the maintenance of virus latency. Given that 
each  microRNA  subtly  influences  the  translation  of 
hundreds of different gene transcripts [264,265], viral 
microRNAs must be involved in many key biological 
processes in virus-infected  cells during latent  infec-
tion,  leading  to  establishment  of  latency  in  tumor Int. J. Biol. Sci. 2010, 6 
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cells. Thus, one can imagine that viral oncogenes do 
not act alone but perhaps coordinate extensively with 
other  viral  products  to  induce  oncogenesis  during 
persistent infection.  
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